RAC 2.92% $1.94 race oncology ltd

Ann: Zantrene AML trial in Israel advances to Phase 2, page-148

  1. 8,405 Posts.
    lightbulb Created with Sketch. 1383
    If RAC had never existed, COH would by now have conducted clinical trials using CS-1.
    There would have been no legal issues.
    There is no way that CS-1 would have been lost.

    The only things that would have been lost are the marketing name "Zantrene" (so what) and the cardioprotection discovery (a big loss).
    Last edited by IndexInvestor: 15/07/23
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.